| |
NTP: Abstract for TR-338 - Erythromycin Stearate |
 | | Erythromycin stearate was studied because of its widespread use in humans as a broad-spectrum macrolide antibiotic and because of the lack of adequate long-term studies for carcinogenicity. |
 | | The average amount of erythromycin stearate consumed per day was approximately 180 or 370 mg/kg for male rats and 210 or 435 mg/kg for female rats; for mice, the average amounts were 270 or 545 mg/kg for males and 250 or 500 mg/kg for females. |
 | | Erythromycin stearate demonstrated equivocal mutagenicity in the mouse L5178Y lymphoma cell assay in the absence of exogenous metabolic activation (S9); erythromycin stearate was not mutagenic in the presence of S9. |
| ntp-server.niehs.nih.gov /index.cfm?objectid=07082F10-BA90-6622-DBE4F889FBEC9D47 (1114 words) |